Immunic AG – Home

Immunic AG is a young biotech company based in the Munich biotech hub Martinsried that develops pharmaceuticals in the immunology space, in particular for autoimmune diseases or diseases that have an important immunology component in its pathogenesis.


Mission of Immunic AG: Immunic AG is a start-up biotech company focused on the development of immune modulators to block TH17- and TH1-mediated immune and autoimmune responses. The final aim is to develop these drug candidates to clinical proof of concept.

Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million

  Omega and Fund+ broaden Immunic’s investor base and add an additional EUR 10 million (USD 12 million) in equity financing Series A financing round now completed with an overall ...
Read More

Immunic Adds EUR 4 Million in Funding to Further Boost Development

Series A financing round extended to EUR 21.7 Million Immunic’s investor base broadened by IBG fund which is managed by bmp Beteiligungsmanagement Expanded funding accelerates further development of IMU-838 and ...
Read More

Immunic strengthens Management Team and Supervisory Board

Two executives with deep understanding of the immunology field, and with experience in the IMU-838/IMU-366 development programs add to the Management Board of Immunic AG – experienced biotech CFO is ...
Read More